Nanohale AG (ETR:FYB) | WebDisclosure

Basculer en Français

11126	Companies
245076	Keywords
173184	Articles
132208	Press releases

Home
Companies
Nanohale AG

PRESS RELEASE

published on 10/21/2025 at 06:30, 11 months 15 days ago

Formycon’s FYB201/Ranivisio® sets innovative standard as Europe’s First Ranibizumab Biosimilar available in Pre-filled Syringe
Formycon's FYB201/Ranivisio® is Europe's First Ranibizumab Biosimilar available in Pre-filled Syringe, offering improved handling, accuracy, and convenience for applicants. Teva to commercialize across Europe

Europe Biosimilar Formycon Teva Ranivisio
BRIEF

published on 10/16/2025 at 06:35, 11 months 20 days ago

Actor Pharmaceuticals et Megalabs s'associent pour la commercialisation du FYB203

Formycon AG Biosimilaire Eylea® Megalabs Acteur Pharmaceutique Commercialisation Du FYB203
BRIEF

published on 10/16/2025 at 06:35, 11 months 20 days ago

Actor Pharmaceuticals and Megalabs Partner for FYB203 Commercialization

Formycon AG Eylea® Biosimilar Actor Pharmaceuticals Megalabs FYB203 Commercialization
PRESS RELEASE

published on 10/16/2025 at 06:30, 11 months 20 days ago

Actor Pharmaceuticals and Megalabs become partners for the commercialization of Formycon’s Eylea® biosimilar FYB203 (aflibercept) for Australia and Latin America
Actor Pharmaceuticals and Megalabs to commercialize Formycon's Eylea biosimilar FYB203 in Australia and Latin America. Partnership agreements include upfront payments and royalties

Partnerships Commercialization Biosimilar Formycon Eylea
BRIEF

published on 10/02/2025 at 06:35, 1 year ago

Formycon Secures U.S. License for Aflibercept Biosimilar

Formycon AG U.S. Market Launch Aflibercept Biosimilar Regeneron Agreement Patent Dispute Resolution
BRIEF

published on 10/02/2025 at 06:35, 1 year ago

Formycon obtient une licence américaine pour le biosimilaire d'Aflibercept

Formycon AG Lancement Sur Le Marché Américain Biosimilaire D'Aflibercept Accord Regeneron Résolution Des Litiges En Matière De Brevets
PRESS RELEASE

published on 10/02/2025 at 06:30, 1 year ago

Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron
Formycon secures U.S. License Date for proposed Aflibercept Biosimilar FYB203 following settlement and license agreement with Regeneron. Commercial launch expected in Q4/2026

Formycon Regeneron Valorum Biologics Aflibercept Biosimilar Patent Disputes
BRIEF

published on 09/17/2025 at 16:00, 1 year ago

Formycon AG: Updated Research and Performance Forecast

Revenue Forecast Biosimilars Formycon FYB202 FYB206
BRIEF

published on 09/17/2025 at 16:00, 1 year ago

Formycon AG : Recherche et prévisions de performance actualisées

Prévisions De Revenus Formycon FYB202 Biosimilaires FYB206
PRESS RELEASE

published on 09/17/2025 at 15:55, 1 year ago

Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research GmbH updates rating on Formycon AG (ISIN: DE000A1EWVY8) to Buy with a target price of €48. Analyst expects revenue to rebound in H2 and Q4 due to FYB202 and FYB206 developments

First Berlin Equity Research BUY Rating Formycon AG Update Target Price

Accesswire

Published on 10/05/2026 at 22:30, 2 hours 44 minutes ago

EV Nickel Announces Formation of Wholly Owned Subsidiary to Advance Nickel Bioleaching Technology and Canadian Nickel Supply Chain
Published on 10/05/2026 at 14:45, 10 hours 29 minutes ago

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives
Published on 10/05/2026 at 14:30, 10 hours 44 minutes ago

Hillcrest and Equipmake Expand Partnership Talks to Include Commercial Licensing of ZVS Technology
Published on 10/05/2026 at 14:30, 10 hours 44 minutes ago

Solitario CEO to Present at John Tumazos Very Independent Research, LLC
Published on 10/05/2026 at 14:00, 11 hours 14 minutes ago

Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth

View all ACCESSWIRE

EQS Group

Published on 10/05/2026 at 22:25, 2 hours 49 minutes ago

LumApps Named a Leader in 2026 Gartner® Magic Quadrant™ for Intranet Packaged Solutions
Published on 10/05/2026 at 22:05, 3 hours 9 minutes ago

AMPERA SUBMITS COMPREHENSIVE ENGAGEMENT PLAN TO THE U.S. NUCLEAR REGULATORY COMMISSION
Published on 10/05/2026 at 21:10, 4 hours 4 minutes ago

Shelly Group Board of Directors considers EUR 70.00 offer price fair and supports Schneider Electric’s voluntary public tender offer
Published on 10/05/2026 at 21:05, 4 hours 9 minutes ago

EQS-Adhoc: Shelly Group SE: Board of Directors with positive opinion on the registered voluntary public tender offer by Schneider Electric SE
Published on 10/05/2026 at 20:15, 4 hours 59 minutes ago

EQS-Adhoc: United Internet AG participates in capital increase against contributions in kind at 1&1 AG

Les Echos

Published on 10/05/2026 at 22:12, 3 hours 2 minutes ago

AXA - Elimination of the dilutive impact of Shareplan 2026
Published on 10/05/2026 at 22:12, 3 hours 2 minutes ago

AXA - Elimination de l'effet dilutif de l'opération Shareplan 2026
Published on 10/05/2026 at 18:13, 7 hours 1 minute ago

Disclosure of shares outstanding and voting rights - 05.10.2026
Published on 10/05/2026 at 18:13, 7 hours 1 minute ago

Déclaration nombre d'actions et droits de vote - 05.10.2026
Published on 10/05/2026 at 18:00, 7 hours 14 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 30 septembre 2026

View all LES ECHOS COMFI WIRE